Skip to main content
Top
Published in: BMC Public Health 1/2022

Open Access 01-12-2022 | SARS-CoV-2 | Research

SARS-CoV-2 sero-prevalence in the workforces of three large workplaces in South Wales: a sero-epidemiological study

Authors: Alice Puchades, Rhian Daniel, John Geen, Jo Peden, Heather Lewis, Kelechi Nnoaham

Published in: BMC Public Health | Issue 1/2022

Login to get access

Abstract

Background

Sero-prevalence studies quantify the proportion of a population that has antibodies against SARS-CoV-2, and can be used to identify the extent of the COVID-19 pandemic at a population level. The aim of the study was to assess the sero-prevalence of SARS-CoV-2 antibodies in the workforce at three workplaces: a food factory, non-food factory and call-centre.

Methods

Nine hundred ninety-three participants were recruited from three workplaces in South Wales. Participants completed a questionnaire and had a lateral flow point-of-care SARS-CoV-2 antibody test administered by a healthcare professional. The data were analysed using multivariable logistic regression, both using complete records only and following multiple imputation.

Results

The sero-prevalence of SARS-CoV-2 antibodies ranged from 4% (n = 17/402) in the non-food factory to 10% (n = 28/281) in the food factory (OR 2.93; 95% CI 1.26 to 6.81). After taking account of confounding factors evidence of a difference remained (cOR comparing food factory to call centre (2.93; 95% CI 1.26 to 6.81) and non-food factory (3.99; 95% CI 1.97 to 8.08) respectively). The SARS-CoV-2 antibody prevalence also varied between roles within workplaces. People working in office based roles had a 2.23 times greater conditional odds (95% CI 1.02 to 4.87) of being positive for SARS-CoV-2 antibodies than those working on the factory floor.

Conclusion

The sero-prevalence of SARS-CoV-2 antibodies varied by workplace and work role. Whilst it is not possible to state whether these differences are due to COVID-19 transmission within the workplaces, it highlights the importance of considering COVID-19 transmission in a range of workplaces and work roles.
Literature
2.
go back to reference Byambasuren O, Cardona M, Bell K, Clark J, McLaws M-L, Glasziou P. Estimating the extent of asymptomatic COVID-19 and its potential for community transmission: systematic review and meta-analysis. J Assoc Med Microbiol Infect Dis Can. 2020;5:223–34. Byambasuren O, Cardona M, Bell K, Clark J, McLaws M-L, Glasziou P. Estimating the extent of asymptomatic COVID-19 and its potential for community transmission: systematic review and meta-analysis. J Assoc Med Microbiol Infect Dis Can. 2020;5:223–34.
4.
go back to reference Deeks JJ, Dinnes J, Takwoingi Y, et al. Cochrane COVID-19 Diagnostic Test Accuracy Group. Antibody tests for identification of current and past infection with SARS-CoV-2[PubMed]. Cochrane Database Syst Rev. 2020;6:CD013652.PubMed Deeks JJ, Dinnes J, Takwoingi Y, et al. Cochrane COVID-19 Diagnostic Test Accuracy Group. Antibody tests for identification of current and past infection with SARS-CoV-2[PubMed]. Cochrane Database Syst Rev. 2020;6:CD013652.PubMed
5.
go back to reference Shields A, Faustini SE, Perez-Toledo M, et al. SARS-CoV-2 seroprevalence and asymptomatic viral carriage in healthcare workers: a cross-sectional study. Thorax. 2020;75:1089–94.CrossRef Shields A, Faustini SE, Perez-Toledo M, et al. SARS-CoV-2 seroprevalence and asymptomatic viral carriage in healthcare workers: a cross-sectional study. Thorax. 2020;75:1089–94.CrossRef
6.
go back to reference Hains DS, Schwaderer AL, Carroll AE, et al. Asymptomatic seroconversion of immunoglobulins to SARS-CoV-2 in a pediatric dialysis unit. JAMA. 2020;323:2424–5. Hains DS, Schwaderer AL, Carroll AE, et al. Asymptomatic seroconversion of immunoglobulins to SARS-CoV-2 in a pediatric dialysis unit. JAMA. 2020;323:2424–5.
7.
go back to reference Chen WQ, Lu CY, Wong TW, et al. Anti–SARS-CoV immunoglobulin G in healthcare workers, Guangzhou, China. Emerg Infect Dis. 2020;11:89–94.CrossRef Chen WQ, Lu CY, Wong TW, et al. Anti–SARS-CoV immunoglobulin G in healthcare workers, Guangzhou, China. Emerg Infect Dis. 2020;11:89–94.CrossRef
8.
go back to reference Xu X, Sun J, Nie S, et al. Seroprevalence of immunoglobulin M and G antibodies against SARS-CoV-2 in China. Nat Med. 2020;26:1193–5.CrossRef Xu X, Sun J, Nie S, et al. Seroprevalence of immunoglobulin M and G antibodies against SARS-CoV-2 in China. Nat Med. 2020;26:1193–5.CrossRef
9.
go back to reference Sood N, Simon P, Ebner P, et al. Seroprevalence of SARS-CoV-2–specific antibodies among adults in Los Angeles County, California, on April 10-11, 2020. JAMA. 2020;323:2425–7.CrossRef Sood N, Simon P, Ebner P, et al. Seroprevalence of SARS-CoV-2–specific antibodies among adults in Los Angeles County, California, on April 10-11, 2020. JAMA. 2020;323:2425–7.CrossRef
10.
go back to reference Pollán M, Pérez-Gómez B, Pastor-Barriuso R, et al. Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study. Lancet. 2020;396:535–44.CrossRef Pollán M, Pérez-Gómez B, Pastor-Barriuso R, et al. Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study. Lancet. 2020;396:535–44.CrossRef
11.
go back to reference Stringhini S, Wisniak A, Piumatti G. Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study. Lancet. 2020;396:313–9.CrossRef Stringhini S, Wisniak A, Piumatti G. Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study. Lancet. 2020;396:313–9.CrossRef
13.
go back to reference Grant J, Wilmore S, McCann N, et al. Seroprevalence of SARS-CoV-2 antibodies in healthcare workers at a London NHS trust. Infect Control Hosp Epidemiol. 2021;42:212–4.CrossRef Grant J, Wilmore S, McCann N, et al. Seroprevalence of SARS-CoV-2 antibodies in healthcare workers at a London NHS trust. Infect Control Hosp Epidemiol. 2021;42:212–4.CrossRef
14.
go back to reference Garcia-Basteiro AL, Moncunill G, Tortajada M, et al. Seroprevalence of antibodies against SARS-CoV-2 among health care workers in a large Spanish reference hospital. Nat Commun. 2020;11:3500.CrossRef Garcia-Basteiro AL, Moncunill G, Tortajada M, et al. Seroprevalence of antibodies against SARS-CoV-2 among health care workers in a large Spanish reference hospital. Nat Commun. 2020;11:3500.CrossRef
18.
go back to reference Middleton J, Reintjes R, Lopes H. Meat plants—a new front line in the covid-19 pandemic. BMJ. 2020;370:m2716.CrossRef Middleton J, Reintjes R, Lopes H. Meat plants—a new front line in the covid-19 pandemic. BMJ. 2020;370:m2716.CrossRef
21.
go back to reference Nibbs L, Morawska L, Bell S. The risk of airborne influenza transmission in passenger cars. Epidemiol Infect. 2012;140:474–8.CrossRef Nibbs L, Morawska L, Bell S. The risk of airborne influenza transmission in passenger cars. Epidemiol Infect. 2012;140:474–8.CrossRef
23.
go back to reference Westreich D, Greenland S. The table 2 fallacy: presenting and interpreting confounder and modifier coefficients. Am J Epidemiol. 2013;177:292–8.CrossRef Westreich D, Greenland S. The table 2 fallacy: presenting and interpreting confounder and modifier coefficients. Am J Epidemiol. 2013;177:292–8.CrossRef
Metadata
Title
SARS-CoV-2 sero-prevalence in the workforces of three large workplaces in South Wales: a sero-epidemiological study
Authors
Alice Puchades
Rhian Daniel
John Geen
Jo Peden
Heather Lewis
Kelechi Nnoaham
Publication date
01-12-2022
Publisher
BioMed Central
Published in
BMC Public Health / Issue 1/2022
Electronic ISSN: 1471-2458
DOI
https://doi.org/10.1186/s12889-021-12478-x

Other articles of this Issue 1/2022

BMC Public Health 1/2022 Go to the issue